Lung SSG 6 th May 2015 Research Wendy Cook, Research Delivery Manager dd/mm/yyyy Delivering clinical research to make patients, and the NHS, better
South West Peninsula CRN Hospital Yeovil District Hospital NHS Foundation Trust Taunton and Somerset NHS Foundation Trust Northern Devon Healthcare NHS Trust Royal Devon and Exeter NHS Foundation Trust South Devon Healthcare NHS Foundation Trust Plymouth Hospitals NHS Trust Size Small Acute Medium Acute Small Acute Large Acute Medium Acute Large Acute Royal Cornwall Hospitals NHS Trust Large Acute
Division 1- Cancer - Contacts Duncan Wheatley, Clinical Specialty Lead duncan.wheatley@rcht.cornwall.nhs.uk 01872 258312 13 sub speciality leads Wendy Cook, Research Delivery Manager wcook1@nhs.net 01392 406995 Ann Courtman, Administrator ann.courtman@nhs.net 01392 406966 Petra Jankowska Lung sub specialty lead petra.jankowska@tst.nhs.uk 01823 343526 3
NIHR Cancer Research Objectives Increase the opportunities for cancer patients to take part in research studies, regardless of where they live Develop action plan to increase access in each subspecialty (e.g by opening studies, increasing awareness and forming referral pathways for access to research) 4
NIHR Cancer Research Objectives Increase the number of cancer patients participating in studies, to support the national target of 20% cancer incidence SW Peninsula Cancer Incidence 12,580 20% = 2,516 pts Current performance 1535pts 12.2% Increase the number of cancer patients participating in interventional trials, to support the national target of 7.5% cancer incidence 7.5% = 944 pts Current performance 714pts 5.7% This is measured on 11 months data from ODP (open data platform) 5
NIHR Cancer Research Objectives Deliver a Portfolio of studies including challenging trials in support of national priorities: Cancer Surgery Radiotherapy Rare cancers (cancers with incidence <6/100,000 year) Children s Cancer & Leukaemia and Teenagers & Young Adults 6
What we need to achieve in each subspecialty group 13 named cancer sub specialty leads with a defined portfolio of studies Highlight, promote studies Promote referral pathways throughout the network Research Subspecialty Lead Participate in national meetings to collaborate with other sub-speciality leads identify studies to bring to the region Connection with CSG s, feedback re sub specialty portfolio and availability of trials for all. 7
SWP Lung 2013/14 and 2014/15 Recruitment by Study Trust Study Acronym Main Topic Disease Study Type Study Design PHT NCRN - 2509 Tremelimumab vs. placebo in Unresectable Pleural or Peritoneal Malignant mesothelioma 2013/14 2014/15 Recruitment Recruitment Mesothelioma Commercial Interventional 0 6 PHT NCRN636 - VS-6063 in mesothelioma Mesothelioma Commercial Interventional 0 1 RCHT NCRN387: Ipi + Etoposide/Platinum vs Etoposide/Platinum in Subjects (ED-SCLC) Lung (small cell) Commercial Interventional 4 0 PHT STOMP Lung (small cell) Non-Commercial Both 0 2 PHT MALCS (Mesothelioma and Lung Cancer Study) Lung (non-small cell), Lung (small cell), Mesothelioma Non-Commercial Observational 4 0 S Devon MALCS (Mesothelioma and Lung Cancer Study) Lung (non-small cell), Lung (small cell), Mesothelioma Non-Commercial Observational 1 0 TST MALCS (Mesothelioma and Lung Cancer Study) Lung (non-small cell), Lung (small cell), Mesothelioma Non-Commercial Observational 6 0 TST TIMELY Lung (non-small cell), Lung (small cell) Non-Commercial Interventional 1 0 RD&E ET Trial Lung (non-small cell) Non-Commercial Interventional 1 0 RCHT GEM (EORTC 08114) Lung (non-small cell) Non-Commercial Observational 0 14 PHT RD&E RD&E RD&E RCHT S Devon NCRN - 2226 - denosumab + chemo in metastatic NSCLC NCRN - 2226 - denosumab + chemo in metastatic NSCLC NCRN - 2974 VESTA: Veliparib, carboplatin & paclitaxel in NSCLC NCRN285 LUX-Lung 8 - afatinib vs erlotinib in advanced lung Ca after 1st line platinum-based chemo NCRN290 IDEATE: Ipilimumab + Paclitaxel + Carboplatin vs Placebo + Paclitaxel in NSCLC QUARTZ Lung (non-small cell) Commercial Interventional 0 2 Lung (non-small cell) Commercial Interventional 0 4 Lung (non-small cell) Commercial Interventional 0 1 Lung (non-small cell) Commercial Interventional 1 0 Lung (non-small cell) Commercial Interventional 5 0 Brain and Nervous System, Lung (non-small cell) Non-Commercial Interventional 1 0 TST LungCAST - Non-Commercial Observational 25 13 Data from Portfolio ODP Cut off 17/04/15
SW Peninsula Lung 2014/15 Recruitment Breakdown Data from ODP Cut off 17/04/15 9
National Lung Recruitment by all 15 Networks Data from ODP Cut off 17/04/15 10
Lung Recruitment National Overview CRN 2013/14 2014/15 East Midlands 171 166 Eastern 347 517 Greater Manchester 294 324 Kent, Surrey and Sussex 42 64 North East and North Cumbria 79 84 North Thames 95 353 North West Coast 715 634 North West London 129 99 Data from ODP Cut off 17/04/15 South London 243 261 South West Peninsula 49 43 Thames Valley and South Midlands 45 54 Wessex 98 336 West Midlands 758 488 West of England 229 190 Yorkshire and Humber 546 292
Portfolio Map Link http://csg.ncri.org.uk/portfolio-maps/ See separate attachment for complete national recruitment by all 15 networks 12
Cancer Research Symposium From Clinical Trials to Clinical Practice Hosted by RD&E Jenny Forrest & Kate Scatchard, Consultant Clinical Oncologists at Gipsy Hill Hotel, Exeter Friday 15 th May 2015 Contact ann.courtman@nhs.net for more information on 01392 406996 13
Thank you Any questions? 14